Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

TuHURA Biosciences And Kintara Therapeutics Announce Phase 1b Trial Of IFx-2.0 In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma And Cutaneous Squamous Cell Carcinoma Results

Author: Benzinga Newsdesk | June 03, 2024 08:36am

TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeks

Eighty percent (80%) of ICI naïve patients with advanced MCC who failed to respond to pembrolizumab or avelumab therapy achieved a durable Complete Response (CR), pathologic CR or Partial Response (PR) following IFx-2.0 therapy and rechallenge with an anti-PD(L)-1 checkpoint inhibitor

Data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Posted In: KTRA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist